APA (7th ed.) Citation

Alvi, R. M., Neilan, A. M., Tariq, N., Awadalla, M., Banerji, D., Rokicki, A., . . . Neilan, T. (2018). RITONAVIR-BASED ANTI-RETROVIRAL THERAPY IS ASSOCIATED WITH A LOWER EJECTION FRACTION AND AN INCREASED RISK FOR DECOMPENSATED HEART FAILURE AND CARDIOVASCULAR MORTALITY AMONG PERSONS LIVING WITH HIV. Journal of the American College of Cardiology (JACC), 71, A883. https://doi.org/10.1016/S0735-1097(18)31424-4

Chicago Style (17th ed.) Citation

Alvi, Raza M., Anne M. Neilan, Noor Tariq, Magid Awadalla, Dahlia Banerji, Adam Rokicki, Virginia Triant, Markella V. Zanni, and Tomas Neilan. "RITONAVIR-BASED ANTI-RETROVIRAL THERAPY IS ASSOCIATED WITH A LOWER EJECTION FRACTION AND AN INCREASED RISK FOR DECOMPENSATED HEART FAILURE AND CARDIOVASCULAR MORTALITY AMONG PERSONS LIVING WITH HIV." Journal of the American College of Cardiology (JACC) 71 (2018): A883. https://doi.org/10.1016/S0735-1097(18)31424-4.

MLA (9th ed.) Citation

Alvi, Raza M., et al. "RITONAVIR-BASED ANTI-RETROVIRAL THERAPY IS ASSOCIATED WITH A LOWER EJECTION FRACTION AND AN INCREASED RISK FOR DECOMPENSATED HEART FAILURE AND CARDIOVASCULAR MORTALITY AMONG PERSONS LIVING WITH HIV." Journal of the American College of Cardiology (JACC), vol. 71, 2018, p. A883, https://doi.org/10.1016/S0735-1097(18)31424-4.